Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.

Taofeek K. Owonikoko,Kyriakos P. Papadopoulos,Melissa Lynne Johnson,Marta Gil-Martin,Victor Moreno,April K. Salama,Emiliano Calvo,Nelson Shu-Sang Yee,Howard Safran,Antonio González-Martín,Raid Aljumaily,Daruka Mahadevan,Jiaxin Niu,Kosalai Kal Mohan,Jingjin Li,Elizabeth Stankevich,Israel Lowy,Matthew G. Fury,Hani M. Babiker

Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.

2018

Taofeek K. Owonikoko
Kyriakos P. Papadopoulos
Melissa Lynne Johnson
Marta Gil-Martin
Victor Moreno
April K. Salama
Emiliano Calvo
Nelson Shu-Sang Yee
Howard Safran
Antonio González-Martín
Raid Aljumaily
Daruka Mahadevan
Jiaxin Niu
Kosalai Kal Mohan
Jingjin Li
Elizabeth Stankevich
Israel Lowy
Matthew G. Fury
Hani M. Babiker

9557Background: Initial analysis of expansion cohorts (ECs) patients in a phase 1 study showed that cemiplimab (REGN2810) demonstrated a positive risk/benefit profile and produced antitumor activit...

Keywords:

Cutaneous squamous cell carcinoma
Pathology
Cancer research
Monoclonal
Medicine
in patient
Oncology
Internal medicine
locally advanced
anti pd 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations